Medications & Complications

Medications

ZENAPAX® (Daclizumab)

Purpose:
Used in combination with standard immunosuppressive agents. It is the first genetically engineered drug to reduce the risk of organ rejection in kidney transplant patients without increasing overall side effects.

How to take:
ZENAPAX is used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids. The recommended dose for ZENAPAX is 1.0 mg/kg. The calculated volume of ZENAPAX should be mixed with 50 mL of sterile 0.9% sodium chloride solution and administered via a peripheral or central vein over a 15-minute period.

Based on the clinical trials, the standard course of ZENAPAX therapy is five doses. The first dose should be given no more than 24 hours before transplantation. The four remaining doses should be given at intervals of 14 days.

No dosage adjustment is necessary for patients with severe renal impairment. No dosage adjustments based on other identified covariates (age, gender, proteinuria, race) are required for renal allograft patients. No data are available for administration in patients with severe hepatic impairment.

Precautions:
General: It is not known whether ZENAPAX use will have a long-term effect on the ability of the immune system to respond to antigens first encountered during ZENAPAX-induced immunosuppression.

Re-administration of ZENAPAX after an initial course of therapy has not been studied in humans. The potential risks of such re-administration, specifically those associated with immunosuppression and/or the occurrence of anaphylaxis/anaphylactoid reactions, are not known.

Principal Side effects:
The following adverse events occurred in >5% of ZENAPAX-treated patients.

  • Gastrointestinal System: constipation, nausea, diarrhea, vomiting, abdominal pain, pyrosis, dyspepsia, abdominal distention, epigastric pain not food-related

  • Metabolic and Nutritional: edema extremities, edema

  • Central and Peripheral Nervous System: tremor, headache, dizziness

  • Urinary System: oliguria, dysuria, renal tubular necrosis

  • Body as a Whole -- General: post-traumatic pain, chest pain, fever, pain, fatigue

  • Autonomic Nervous System: hypertension, hypotension, aggravated hypertension

  • Respiratory System: dyspnea, pulmonary edema, coughing

  • Skin and Appendages: impaired wound healing without infection, acne

  • Psychiatric: insomnia; Musculoskeletal System: musculoskeletal pain, back pain

  • Heart Rate and Rhythm: tachycardia; Vascular Extracardiac: thrombosis

  • Platelet, Bleeding and Clotting Disorders: bleeding

  • Hemic and Lymphatic: lymphocele


<Back      Return to: Medications

Home Page  |  Glossary  |  Site Map
University of Southern California USC Liver Transplant Program and Center for Liver Disease
1510 San Pablo Street, Suite 200, Los Angeles CA 90033-4612
Phone: (323) 442-5908     Fax: (323) 442-5721
E-mail: uscliver@surgery.hsc.usc.edu